2 documents found, page 1 of 1
Evaluation of real-world mepolizumab use in severe asthma across Europe: the SH...
Kroes, Johannes A; Alfonso-Cristancho, Rafael; Bansal, Aruna T; Berret, Emmanuelle; Bieksiene, Kristina; Bourdin, Arnaud; Brussino, LuisaBackground An objective of the Severe Heterogeneous Asthma Registry, Patient-centered (SHARP) is to produce real-world evidence on a pan-European scale by linking nonstandardised, patient-level registry data. Mepolizumab has shown clinical efficacy in randomised controlled trials and prospective real-world studies and could therefore serve as a proof of principle for this novel approach. The aim of the present ...
Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients...
Pfeffer, Paul E.; Ali, Nasloon; Murray, Ruth; Ulrik, Charlotte; Tran, Trung N.; Maspero, Jorge; Peters, Matthew; Christoff, George C.Background: Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti-IgE and anti-IL5/ 5R and to compare the effectiveness of both classes of treatment in real life. Methods: This was a prospective cohort study that inc...